Chikungunya virus and the safety of plasma products

Transfusion

Volumn 52, Issue 10, 2012, Pages 2122-2130

  Leydold, Sandra M ^a   Farcet, Maria R ^a   Kindermann, Johanna ^a   Modrof, Jens ^a   Pölsler, Gerhard ^a   Berting, Andreas ^a   Howard, M Keith ^a   Barrett, P Noel ^a   Kreil, Thomas R ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; DETERGENT; HUMAN SERUM ALBUMIN; IMMUNOGLOBULIN; SOLVENT;

ARTICLE; BLOOD SAFETY; BOVINE VIRAL DIARRHEA; CHIKUNGUNYA ALPHAVIRUS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; HEATING; NONHUMAN; PASTEURIZATION; PH; SINDBIS VIRUS; VAPOR HEATING; VIRUS INACTIVATION; WEST NILE FLAVIVIRUS;

ACIDS; AGED; ALPHAVIRUS INFECTIONS; ANIMALS; BLOOD COAGULATION FACTORS; BLOOD SAFETY; CELL LINE; CHIKUNGUNYA VIRUS; COMMUNICABLE DISEASES, EMERGING; DETERGENTS; DISEASE OUTBREAKS; FREEZE DRYING; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULINS, INTRAVENOUS; PASTEURIZATION; PLASMA; SERUM ALBUMIN; SINDBIS VIRUS; SURFACE-ACTIVE AGENTS; VIRAL LOAD; VIREMIA; VIRUS INACTIVATION; WEST NILE VIRUS; WORLD HEALTH;

EID: 84868301376     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03565.x     Document Type: Article

References (27)

1. Brouard C, Bernillon P, Quatresous I, Pillonel J, Assal A, De Valk H, Desenclos JC,. Estimated risk of Chikungunya viremic blood donation during an epidemic on Reunion Island in the Indian Ocean, 2005 to 2007. Transfusion 2008; 48: 1333-41.
2. Simon F, Savini H, Parola P,. Chikungunya: a paradigm of emergence and globalization of vector-borne diseases. Med Clin North Am 2008; 92: 1323-43.
3. Charrel RN, de Lamballerie X, Raoult D,. Chikungunya outbreaks-the globalization of vectorborne diseases. N Engl J Med 2007; 356: 769-71.
4. Tsetsarkin KA, Vanlandingham DL, McGee CE, Higgs S,. A single mutation in chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007; 3: e201.
5. Gratz NG,. Critical review of the vector status of Aedes albopictus. Med Vet Entomol 2004; 18: 215-27.
6. Gibney KB, Fischer M, Prince HE, Kramer LD, St George K, Kosoy OL, Laven JJ, Staples JE,. Chikungunya fever in the United States: a fifteen year review of cases. Clin Infect Dis 2011; 52: e121-e126.
7. Parola P, de Lamballerie X, Jourdan J, Rovery C, Vaillant V, Minodier P, Brouqui P, Flahault A, Raoult D, Charrel RN,. Novel chikungunya virus variant in travelers returning from Indian Ocean islands. Emerg Infect Dis 2006; 12: 1493-9.
8. Rezza G, Nicoletti L, Angelini R, Romi R, Finarelli AC, Panning M, Cordioli P, Fortuna C, Boros S, Magurano F, Silvi G, Angelini P, Dottori M, Ciufolini MG, Majori GC, Cassone A,; CHIKV study group. Infection with chikungunya virus in Italy: an outbreak in a temperate region. Lancet 2007; 370: 1840-6.
9. Angelini R, Finarelli AC, Angelini P, Po C, Petropulacos K, Silvi G, Macini P, Fortuna C, Venturi G, Magurano F, Fiorentini C, Marchi A, Benedetti E, Bucci P, Boros S, Romi R, Majori G, Ciufolini MG, Nicoletti L, Rezza G, Cassone A,. Chikungunya in north-eastern Italy: a summing up of the outbreak. Euro Surveill 2007; 12: E071122.
10. Angelini P, Macini P, Finarelli AC, Pol C, Venturelli C, Bellini R, Dottori M,. Chikungunya epidemic outbreak in Emilia-Romagna (Italy) during summer 2007. Parassitologia 2008; 50: 97-8.
11. Grandadam M, Caro V, Plumet S, Thiberge JM, Souares Y, Failloux AB, Tolou HJ, Budelot M, Cosserat D, Leparc-Goffart I, Desprès P,. Chikungunya virus, southeastern France. Emerg Infect Dis 2011; 17: 910-3.
12. Liumbruno GM, Calteri D, Petropulacos K, Mattivi A, Po C, Macini P, Tomasini I, Zucchelli P, Silvestri AR, Sambri V, Pupella S, Catalano L, Piccinini V, Calizzani G, Grazzini G,. The Chikungunya epidemic in Italy and its repercussion on the blood system. Blood Transfus 2008; 6: 199-210.
13. Sissoko D, Moendandze A, Malvy D, Giry C, Ezzedine K, Solet JL, Pierre V,. Seroprevalence and risk factors of chikungunya virus infection in Mayotte, Indian Ocean, 2005-2006: a population-based survey. PLoS ONE 2008; 3: e3066.
14. United States Food and Drug Administration Center for Biologics Evaluation and Research, Public Workshop. Emerging Arboviruses: evaluating the threat to transfusion and transfusion safety. Bethesda (MD): Natcher Conference Center, National Institutes of Health; 2009.
15. European Medicines Agency/Committee for Medicinal Products for human use (CHMP). Guideline on plasma derived medicinal products-revised (EMA/CHMP/BWP/706271/2010). 2011.
16. The European Agency for the Evaluation of Medicinal Products/Committee for Proprietary Medicinal Products (CPMP). Note for guidance on virus validation studies: the design, contribution and interpretation of studies validating the inactivation and removal of viruses. CPMP/BWP/268/95/rev. 1996.
17. Kreil TR, Berting A, Kistner O, Kindermann J,. West Nile virus and the safety of plasma derivatives: verification of high safety margins, and the validity of predictions based on model virus data. Transfusion 2003; 43: 1023-8.
18. Kreil TR, Unger U, Orth SM, Petutschnig G, Kistner O, Poelsler G, Berting A,. H5N1 influenza virus and the safety of plasma products. Transfusion 2007; 47: 452-9.
19. Beasley DW, Li L, Suderman MT, Barrett AD,. Mouse neuroinvasive phenotype of West Nile virus strains varies depending upon virus genotype. Virology 2002; 296: 17-23.
20. Unger U, Poelsler G, Modrof J, Kreil TR,. Virus inactivation during the freeze-drying processes as used for the manufacture of plasma-derived medicinal products. Transfusion 2009; 49: 1924-30.
21. Petersen LR, Roehrig JT,. West Nile virus: a reemerging global pathogen. Emerg Infect Dis 2001; 7: 611-4.
22. Roberts PL, Dunkerley C, McAuley A, Winkelman L,. Effect of manufacturing process parameters on virus inactivation by dry heat treatment at 80 degrees C in factor VIII. Vox Sang 2007; 92: 56-63.
23. Roberts PL,. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII. Biologicals 2008; 36: 330-5.
24. Remington KM, Trejo SR, Buczynski G, Li H, Osheroff WP, Brown JP, Renfrow H, Reynolds R, Pifat DY,. Inactivation of West Nile virus, vaccinia virus and viral surrogates for relevant and emergent viral pathogens in plasma-derived products. Vox Sang 2004; 87: 10-8.
25. Dichtelmüller HO, Biesert L, Fabbrizzi F, Gajardo R, Groner A, von Hoegen I, Jorquera JI, Kempf C, Kreil TR, Pifat D, Osheroff W, Poelsler G,. Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Protein Therapeutics Association member companies. Transfusion 2009; 49: 1931-43.
26. Horowitz B, Lazo A, Grossberg H, Page G, Lippin A, Swan G,. Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma. Vox Sang 1998; 74 Suppl 1: 203-6.
27. Fritz R, Stiasny K, Heinz FX,. Identification of specific histidines as pH sensors in flavivirus membrane fusion. J Cell Biol 2008; 183: 353-61.